ArticleBritish journal of pharmacology2005
Captopril improves cerebrovascular structure and function in old hypertensive rats.
Article in British journal of pharmacology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- Trial
- Stroke attributed to kidney dysfunction from 1990 to 2021 and the prediction for 2040: an analysis of national data in China based on the Global Burden of Disease 2021 database.BMC public health · 2025Article
- Systemic and Cardiac Microvascular Dysfunction in Hypertension.International journal of molecular sciences · 2024Review
- Association between life's essential 8 and cognitive impairment in older patients: results from NHANES 2011-2014.BMC geriatrics · 2024Article
- Angiotensin II-mediated hippocampal hypoperfusion and vascular dysfunction contribute to vascular cognitive impairment in aged hypertensive rats.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Hypertension, Neurovascular Dysfunction, and Cognitive Impairment.Hypertension (Dallas, Tex. : 1979) · 2023Review
- Pathogenetic Mechanisms of Hypertension-Brain-Induced Complications: Focus on Molecular Mediators.International journal of molecular sciences · 2022Review
- Targeting the Angiotensin II Type 1 Receptor in Cerebrovascular Diseases: Biased Signaling Raises New Hopes.International journal of molecular sciences · 2021Review
- An integrated set-up for ex vivo characterisation of biaxial murine artery biomechanics under pulsatile conditions.Scientific reports · 2021Article
- Mangiferin Alleviates Renal Interstitial Fibrosis in Streptozotocin-Induced Diabetic Mice through Regulating the PTEN/PI3K/Akt Signaling Pathway.Journal of diabetes research · 2020Article
- Mechanisms and treatment of late-life depression.Translational psychiatry · 2019Review
- Hypertension Induced Morphological and Physiological Changes in Cells of the Arterial Wall.American journal of hypertension · 2018Review
- Recent Progress in Vascular Aging: Mechanisms and Its Role in Age-related Diseases.Aging and disease · 2017Review
- Metformin ameliorates diabetic nephropathy in a rat model of low-dose streptozotocin-induced diabetes.Experimental and therapeutic medicine · 2017Article
- Cerebrovasculoprotective effects of azilsartan medoxomil in diabetes.Translational research : the journal of laboratory and clinical medicine · 2014Article
- Impact of the neutrophil response to granulocyte colony-stimulating factor on the risk of hemorrhage when used in combination with tissue plasminogen activator during the acute phase of experimental stroke.Journal of neuroinflammation · 2014Article
- The effects of obesity on the cerebral vasculature.Current vascular pharmacology · 2014Review
- Vasotrophic regulation of age-dependent hypoxic cerebrovascular remodeling.Current vascular pharmacology · 2013Review
- The effects of hypertension on the cerebral circulation.American journal of physiology. Heart and circulatory physiology · 2013Review
- Neutrophils contribute to intracerebral haemorrhages after treatment with recombinant tissue plasminogen activator following cerebral ischaemia.British journal of pharmacology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We examined the effects of an angiotensin-converting enzyme inhibitor (ACEI), captopril, on cerebral arterioles in young and old spontaneously hypertensive rats (SHR). Animals were anesthetized with sodium pentobarbitone (60 mg kg(-1) day(-1)). We measured cerebral blood flow (CBF, arbitrary units) and cerebral arteriolar internal diameter (ID, mum) prior to and during stepwise hypotension (SH) in 6- (WKY-6) and 15-month-old (WKY-15) Wistar Kyoto rats and in age-matched SHR that were untreated (SHR-6 and SHR-15) or treated for 3 months with captopril (SHR-6C, 105+/-2 mg kg(-1) day(-1) and SHR-15C, 94+/-1 mg kg(-1) day(-1)). ID and cross-sectional area of the vessel wall (CSA) were measured in deactivated (EDTA) cerebral arterioles during a second SH. Captopril decreased the lower limit of CBF autoregulation (61+/-6 in SHR-6C and 51+/-2 in SHR-15C vs 52+/-6 in WKY-6 and 62+/-7 in WKY-15 and 83+/-14 mmHg in SHR-6 and 120+/-19 mmHg in SHR-15; P<0.05) and CSA (510+/-21 in SHR-6C and 585+/-25 in SHR-15C vs 529+/-12 in WKY-6 and 549+/-20 in WKY-15 and 644+/-38 mmHg in SHR-6 and 704+/-38 mmHg in SHR-15; P<0.05). Captopril increased cerebral arteriolar external diameter of SHR (105+/-5 in SHR-6C and 94+/-4 in SHR-15C vs 125+/-8 in WKY-6 and 108+/-3 in WKY-15 and 83+/-2 mmHg in SHR-6 and 80+/-2 mmHg in SHR-15 for a pial arteriolar pressure step of 35-39 mmHg; P<0.05). Captopril attenuated increases in cerebral arteriolar distensibility in young SHR. Thus, ACEIs attenuate eutrophic and hypertrophic inward remodeling of cerebral arterioles in young and old SHR, thus decreasing the lower limit of CBF autoregulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.